このエントリーをはてなブックマークに追加
ID 63521
FullText URL
fulltext.pdf 2.27 MB
Author
Nishimura, Yoshito Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID publons researchmap
Nishikori, Asami Division of Pathophysiology, Okayama University Graduate School of Health Sciences
Sawada, Haruki Department of Medicine, University of Hawaii
Czech, Torrey Department of Medicine, University of Hawaii
Otsuka, Yuki Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Nishimura, Midori Filiz Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Mizuno, Hiroki Nephrology Center, Toranomon Hospital Kajigaya
Sawa, Naoki Nephrology Center, Toranomon Hospital Kajigaya
Momose, Shuji Department of Pathology, Saitama Medical Center, Saitama Medical University
Ohsawa, Kumiko Division of Pathophysiology, Okayama University Graduate School of Health Sciences
Otsuka, Fumio Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
Sato, Yasuharu Division of Pathophysiology, Okayama University Graduate School of Health Sciences ORCID Kaken ID researchmap
Abstract
Idiopathic multicentric Castleman disease (iMCD) is a systemic disorder characterized by systemic inflammation and organ dysfunction associated with an increase in pro-inflammatory cytokines. Some patients with iMCD are positive for autoantibodies, although their significance and relationship with specific associated autoimmune diseases are unclear. This study retrospectively analyzed the clinicopathological features of iMCD patients focusing on autoantibodies. Among 63 iMCD patients in our database, 19 were positive for at least one autoantibody. Among the 19, we identified five with plasma cell type (PC)-iMCD lymph node histopathology and positive anti-phospholipid antibodies. These patients were likely to have thrombocytopenia, anasarca, fever, reticulin fibrosis or renal insufficiency, organomegaly (TAFRO) symptoms, and thrombotic events. The present study suggests that patients with undiagnosed or atypical autoimmune diseases, including anti-phospholipid syndrome (APS), were treated for iMCD. APS may present with thrombocytopenia or even multi-organ failure, which overlap with clinical presentations of iMCD. Due to differences in the treatment regimen and follow-up, recognition of the undiagnosed autoimmune disease process in those suspected of iMCD is essential. Our study highlights the importance of complete exclusion of differential diagnoses in patients with iMCD in their diagnostic workup.
Keywords
idiopathic plasmacytic lymphadenopathy
multicentric Castleman disease
autoimmune
anti-phospholipid syndrome
Published Date
2022
Publication Title
Journal Of Clinical And Experimental Hematopatholo
Publisher
The Japanese Society for Lymphoreticular Tissue Research
Start Page
21038
ISSN
1346-4280
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
Copyright Holders
© 2022 The Japanese Society for Lymphoreticular Tissue Research
File Version
publisher
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.3960/jslrt.21038
License
https://creativecommons.org/licenses/by-nc-sa/4.0/